X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs STRIDES PHARMA SCIENCE - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. STRIDES PHARMA SCIENCE WOCKHARDT LTD./
STRIDES PHARMA SCIENCE
 
P/E (TTM) x -19.2 52.2 - View Chart
P/BV x 2.0 1.1 179.2% View Chart
Dividend Yield % 0.0 0.4 0.4%  

Financials

 WOCKHARDT LTD.   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
WOCKHARDT LTD./
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,0121,147 88.2%   
Low Rs532642 82.8%   
Sales per share (Unadj.) Rs355.9317.2 112.2%  
Earnings per share (Unadj.) Rs-60.37.8 -768.4%  
Cash flow per share (Unadj.) Rs-46.825.1 -186.6%  
Dividends per share (Unadj.) Rs0.012.00 0.5%  
Dividend yield (eoy) %00.2 0.6%  
Book value per share (Unadj.) Rs257.8274.3 94.0%  
Shares outstanding (eoy) m110.6389.50 123.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.22.8 76.9%   
Avg P/E ratio x-12.8114.0 -11.2%  
P/CF ratio (eoy) x-16.535.7 -46.2%  
Price / Book Value ratio x3.03.3 91.8%  
Dividend payout %025.5 -0.1%   
Avg Mkt Cap Rs m85,37980,058 106.6%   
No. of employees `0006.32.5 249.5%   
Total wages/salary Rs m9,3714,341 215.9%   
Avg. sales/employee Rs Th6,295.011,325.8 55.6%   
Avg. wages/employee Rs Th1,498.31,731.4 86.5%   
Avg. net profit/employee Rs Th-1,066.3280.1 -380.7%   
INCOME DATA
Net Sales Rs m39,36928,394 138.7%  
Other income Rs m1,202941 127.8%   
Total revenues Rs m40,57129,334 138.3%   
Gross profit Rs m183,965 0.5%  
Depreciation Rs m1,4951,540 97.1%   
Interest Rs m2,5551,962 130.2%   
Profit before tax Rs m-2,8301,403 -201.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m-3,582-436 821.9%   
Tax Rs m25797 264.1%   
Profit after tax Rs m-6,669702 -949.8%  
Gross profit margin %014.0 0.3%  
Effective tax rate %-9.16.9 -131.0%   
Net profit margin %-16.92.5 -685.0%  
BALANCE SHEET DATA
Current assets Rs m33,79624,836 136.1%   
Current liabilities Rs m26,91718,993 141.7%   
Net working cap to sales %17.520.6 84.9%  
Current ratio x1.31.3 96.0%  
Inventory Days Days7971 111.8%  
Debtors Days Days89113 78.7%  
Net fixed assets Rs m39,66434,289 115.7%   
Share capital Rs m553895 61.8%   
"Free" reserves Rs m27,96823,651 118.3%   
Net worth Rs m28,52224,546 116.2%   
Long term debt Rs m21,73115,513 140.1%   
Total assets Rs m81,62065,437 124.7%  
Interest coverage x-0.11.7 -6.3%   
Debt to equity ratio x0.80.6 120.6%  
Sales to assets ratio x0.50.4 111.2%   
Return on assets %-5.04.1 -123.8%  
Return on equity %-23.42.9 -817.4%  
Return on capital %-7.76.9 -111.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80715,697 62.5%   
Fx outflow Rs m1,789735 243.2%   
Net fx Rs m8,01914,962 53.6%   
CASH FLOW
From Operations Rs m6841,871 36.6%  
From Investments Rs m6,3025,826 108.2%  
From Financial Activity Rs m-7,695-10,157 75.8%  
Net Cashflow Rs m-664-2,615 25.4%  

Share Holding

Indian Promoters % 74.5 27.7 269.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 37.8 6.1%  
FIIs % 7.7 8.6 89.5%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 25.9 59.5%  
Shareholders   67,757 56,241 120.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 150 Points Up; Oil & Gas Stocks Lead(09:30 am)

Asian stock markets are lower today as Japanese and Hong Kong shares show losses. The Nikkei 225 is up 0.3% while the Hang Seng is down 0.1%.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Nov 14, 2018 11:49 AM

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 8-QTR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS